{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:35:28Z","timestamp":1774604128753,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cca.2022.11.011","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T13:32:20Z","timestamp":1669469540000},"page":"216-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon"],"prefix":"10.1016","volume":"538","author":[{"given":"Jill","family":"Vercruyssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Els","family":"Bailleul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2022.11.011_b0005","first-page":"ijlh.13342","article-title":"Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory","author":"Siriez","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.cca.2022.11.011_b0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cca.2022.11.011_b0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.14398","article-title":"Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis","volume":"17","author":"Elsebaie","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cca.2022.11.011_b0020","doi-asserted-by":"crossref","unstructured":"D.M. Adcock, R. Gosselin, Direct oral anticoagulants (DOACs) in the laboratory: 2015 review, Thrombosis Res. 136 (2015) 7\u201312, doi: 10.1016\/j.thromres.2015.05.001.","DOI":"10.1016\/j.thromres.2015.05.001"},{"key":"10.1016\/j.cca.2022.11.011_b0025","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ijlh.12065","article-title":"Novel anticoagulants and laboratory testing","volume":"35","author":"Eby","year":"2013","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.cca.2022.11.011_b0030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ijlh.12528","article-title":"Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays","volume":"38","author":"Gosselin","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.cca.2022.11.011_b0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pathol.2015.11.025","article-title":"The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples","volume":"48","author":"Bonar","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.cca.2022.11.011_b0040","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ijlh.12807","article-title":"The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays","volume":"40","author":"Jacquemin","year":"2018","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.cca.2022.11.011_b0045","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/jth.13138","article-title":"The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders","volume":"13","author":"Jacquemin","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cca.2022.11.011_b0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/JBM.S121550","article-title":"Reversing factor Xa inhibitors \u2013 clinical utility of andexanet alfa","volume":"8","author":"Kaatz","year":"2017","journal-title":"J. Blood Med."},{"key":"10.1016\/j.cca.2022.11.011_b0055","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1160\/TH16-03-0224","article-title":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban","volume":"117","author":"Ansell","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cca.2022.11.011_b0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ijlh.12950","article-title":"Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban","volume":"41","author":"Platton","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.cca.2022.11.011_b0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.thromres.2018.01.047","article-title":"Simple method for removing DOACs from plasma samples","volume":"163","author":"Exner","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cca.2022.11.011_b0070","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/ijlh.13267","article-title":"Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples","volume":"42","author":"Sevenet","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.cca.2022.11.011_b0075","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/jth.14488","article-title":"Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon","volume":"17","author":"Frans","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cca.2022.11.011_b0080","first-page":"491","article-title":"Interference of direct oral anticoagulants in haemostasis assays: high potential for diagnostic false positives and false negatives","volume":"15","author":"Favaloro","year":"2017","journal-title":"Blood Transfus."},{"key":"10.1016\/j.cca.2022.11.011_b0085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1309\/AJCPY6G6ZITVKPVH","article-title":"The effect of Dabigatran on select specialty coagulation assays","volume":"139","author":"Adcock","year":"2013","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.cca.2022.11.011_b0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5858\/arpa.2020-0021-OA","article-title":"The effect of direct oral anticoagulants on antithrombin activity testing is abolished by DOAC-stop in venous thromboembolism patients","volume":"145","author":"Z\u0105bczyk","year":"2021","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.cca.2022.11.011_b0095","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1365-2516.2008.01830.x","article-title":"Inherited antithrombin deficiency: a review","volume":"14","author":"Patnaik","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.cca.2022.11.011_b0100","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16776","article-title":"Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis","author":"Baker","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.cca.2022.11.011_b0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jth.14648","article-title":"Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH","volume":"18","author":"Van Cott","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cca.2022.11.011_b0110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1160\/TH17-08-0568","article-title":"Activated factor X-based versus thrombin-based antithrombin testing in thrombophilia workup in the DOAC era","volume":"118","author":"R\u00fchl","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cca.2022.11.011_b0115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ijlh.12219","article-title":"Laboratory testing issues for protein C, protein S, and antithrombin","volume":"36","author":"Marlar","year":"2014","journal-title":"Int. J. Lab. Hematol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122013705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122013705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:09:44Z","timestamp":1757862584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898122013705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":23,"alternative-id":["S0009898122013705"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2022.11.011","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2022.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}